Notably, we found that endogenous IGF2BP2 levels in lung cancer cells were significantly increased by various autophagy inhibitors, including Bafilomycin A1, 3-MA and NH4Cl (Supplementary Fig. 1C), but remarkably reduced by autophagy activators Rapamycin, AZD8055 and EBSS (Supplementary Fig. 1D), strongly suggesting that basal levels of IGF2BP2 are dynamically regulated by a lysosomal system in lung cancer cells. The gene discussed is IGF2BP2; the disease is lung cancer.